XML 26 R5.htm IDEA: XBRL DOCUMENT

STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Total	Common Stock	Additional Paid-in Capital	Retained Deficit
Balance at Feb. 28, 2013	$ (84,662)	$ 131,449	$ 107,883,768	$ (108,099,879)
Balance (in shares) at Feb. 28, 2013		131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski, M.D., Ph.D.	252,900		252,900
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.	2,119,432		2,119,432
Net loss	(2,463,556)			(2,463,556)
Balance at Aug. 31, 2013	$ (175,886)	$ 131,449	$ 110,256,100	$ (110,563,435)
Balance (in shares) at Aug. 31, 2013		131,448,444

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References+ Details